Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Clalit Health Services
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Moderate to severe rheumatoid arthritis
Inadequate response (or intolerant) to non-biological DMARDs or one biologic agent
Patients initiating treatment with RoActemra/Actemra on their physician's decision (in accordance with the local label), including patients who started treatment with RoActemra/Actemra in the 8 weeks prior to the enrolment visit
You may not be if
RoActemra/Actemra treatment more than 8 weeks prior to the enrolment visit
Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use
Enrolled in an ongoing clinical trial and/or treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra
History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis
Clareo Health | Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
